Recent analysis of the iShares U.S. Pharmaceuticals ETF (IHE) and the State Street SPDR S&P Biotech ETF (XBI) highlights the contrasting investment strategies in the healthcare sector. IHE focuses on large, stable pharmaceutical companies providing steady cash flows and dividends, while XBI targets the more volatile biotech industry with its equal-weighted index, introducing higher growth potential but significant risk. Over the past year, XBI has seen remarkable growth, outperforming IHE, but with a steep maximum drawdown in the last five years, underscoring the inherent risks in biotech investments. Investors are advised to choose based on their risk tolerance and investment goals, with IHE being more suitable for conservative investors and XBI for those seeking aggressive growth.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/etfs/2026/08/20/ihe-vs-xbi-pharma-stability-or-biotech-growth-which-healthcare-etf-is-the-better-buy/
